Cashed up biotech stock, now there's a rarity in the current climate
Their cash balance exceeds their market cap at today's price and they have more than sufficient funding to get some potentially exciting anti-inflammatory drugs through testing and to the market over the next couple of years. To top it off, they have an existing and growing revenue stream from patents/licences. So I used some of my cash today for a long-term (3-5 year) play. Check back in 5 years to see how I went.